The Nevada Department of Health and Human Services (DHHS or the Department) is required to compile a list of prescription drugs essential for treating diabetes and asthma in Nevada (Nevada Revised Statutes (NRS) 439B.630). The 2021 Essential Drugs (ED) List was published on February 1, 2021 (Nevada DHHS, 2020a). All manufacturers that produce medication included in Nevada’s ED List are required to submit to DHHS an ED Report with data outlining drug production costs, profits, financial aid, and other drug-specific information and pricing data (NRS 439B.635). For those drugs that experienced a recent significant price increase, manufacturers are required to submit an ED Price Increase Report that provides a justification for these price increases (NRS 439B.640). Pharmacy Benefit Managers (PBMs) are required to submit reports regarding rebates negotiated with manufacturers for Nevada’s EDs (NRS 439B.645). This report will include aggregated information regarding pharmaceutical representative compensation and samples provided to eligible health professionals and staff.